

August 3, 2021

IMAP advises the shareholders of biotech company Xell on sale to Sartorius

IMAP is pleased to announce that the shareholders of Xell AG, a specialist supplier of cell culture media, have sold their shares to Sartorius Stedim Biotech, a division of the listed life science company Sartorius.

Xell, based in Bielefeld, Germany, provides ultra-high-performance culture media and feeds in particular for the production of viral vectors used in gene therapies and vaccines, since its foundation 12 years ago. In addition, the globally operating company offers various analytical services to characterize and quantify media components and optimize media formulations. Two years ago, the company invested in a very extensive and state-of-the-art production facility for powder and liquid culture media.

Sartorius is a leading international partner of the biopharmaceutical industry and life science research sector. By acquiring complementary technologies, Sartorius AG regularly extends its portfolio in the areas of "Lab Products & Services" and "Bioprocess Solutions". During 2020, the company generated revenues of approximately 2.3 billion euros. By the end of 2020 the group employed nearly 11,000 people in more than 110

The IMAP Germany team, led by Dr. Carsten Lehmann, Patrick Fritscher and Isabella Böing, exclusively advised the shareholders of Xell and supported them in preparing, negotiating and successfully closing the transaction.





Dr. Carsten Lehmann Managing Director **IMAP Germany** carsten.lehmann@imap.de



Patrick Fritscher Project Manager / VP IMAP Germany patrick.fritscher@imap.com



Isabella Böing Analyst **IMAP Germany** isabella.boeing@imap.de

For more information on IMAP transactions visit www.imap.com

































